|
Market Report
|
 The Women’s Health Market Outlook to 2011
With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women’s health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes.
|
|
Read more...
|
|
|
Product Report
|
Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity
Drug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines.
|
|
Read more...
|
|
|
Market Report
|
The Global Anti-Infectives Market Outlook to 2011
The anti-infectives market is forecast to expand at a CAGR of 4.8% over the period 2005-11, riven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets.
|
|
Read more...
|
|
|
Product Report
|
Outlook for RNAi, 2007: siRNA and miRNA in biology, diagnostics and therapeutics
RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.
|
|
Read more...
|
|
|
Market Report
|
The Indian Pharmaceutical Market to 2011: Competitive dynamics and major players
Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities.
|
|
Read more...
|
|
|
Product Report
|
Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players
The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole.
|
|
Read more...
|
|
|
Market Report
|
The Global HIV/AIDS Market Outlook to 2012
The Global HIV/AIDS Market Outlook to 2012 is a report that provides comprehensive coverage of the global HIV/AIDS market, incorporating a detailed epidemiological analysis of the prevalence of HIV/AIDS and key factors impacting prevalence in both the seven major pharmaceutical markets as well as emerging markets.
|
|
Read more...
|
|
|
Market Report
|
Patent Protection Strategies: Maximising product Revenues
Patent Protection Strategies: Maximising product revenues explores the best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations.
|
|
Read more...
|
|
|
Market Report
|
Autoimmune Market Outlook to 2012
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years.
|
|
Read more...
|
|
|
Product Report
|
The Future of Biosimilars: Key opportunities & emerging therapies
Biotechnological products are continuing to exhibit substantial revenue gains, with the top 12 biologics registering sales growth of 20%in 2006, amassing a market share of $64 billion. However, the impending patent expiry of many leading products has created a number of highly attractive market opportunities for biosimilars. To exploit this significant potential, a complex route to market must first be negotiated, including numerous barriers to entry and regulatory hurdles.
|
|
Read more...
|
|
|
Product Report
|
Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs&medical devices
Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases.
|
|
Read more...
|
|
|
Market Report
|
Emerging Pharmaceutical Markets:Growth opportunities,changing healthcare dynamics& regulatory trends
The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14.7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US. Emerging Pharmaceutical Markets is a new report published that examines the external, regulatory and competitive environments of emergent markets in 24 countries across Asia, Central and Eastern Europe, and Latin America.
|
|
Read more...
|
|
|
Market Report
|
The CNS Market Outlook to 2012
CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets.
|
|
Read more...
|
|
|
Market Report
|
Biomanufacturing Strategies: Market drivers and opportunities in contract relationship management
The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20.
|
|
Read more...
|
|
|
Market Report
|
Translational Medicine in Biopharmaceutical R&D: Enabling R&D optimization and early detection of potential failures
As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research.
|
|
Read more...
|
|
|
Market Report
|
Drug Development Opportunities in China: Regulation, key players and initiatives for domestic and international
Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization.
|
|
Read more...
|
|
|
Product Report
|
"Immunomodulators: Therapeutic Needs, Pipelines & Prospects"
The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures.
|
|
Read more...
|
|
|
Market Report
|
The Gastrointestinal Market Outlook to 2012
The Gastrointestinal Market Outlook to 2012 provides a detailed epidemiological analysis of key indications within major GIT markets, and examines the factors impacting their prevalence.
|
|
Read more...
|
|
Farmavita.Net Journal 
